Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE-IPF)
Conditions
Interventions
treatment group:On the basis of guideline-directed treatment the treatment group was administered Kangxian Huanji Granule
control group:On the basis of guideline-directed treatment the Kangxian Huanji Granule placebo was administered
Sponsors
The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
40 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Hospitalized patients meeting the diagnostic criteria for Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE-IPF); 2.Patients meeting the standards of Traditional Chinese Medicine (TCM) syndrome differentiation; 3.Age range: 40 to 85 years; 4.Voluntary acceptance of treatment and signing of informed consent.
Exclusion criteria
Exclusion criteria: 1.Patients with other pulmonary diseases such as chronic obstructive pulmonary disease (COPD) lung cancer active pulmonary tuberculosis bronchiectasis or pulmonary embolism; 2.Patients with severe cardiovascular and cerebrovascular diseases (e.g. malignant arrhythmia unstable angina acute myocardial infarction heart function of grade 3 or above stroke or cerebral hemorrhage); 3.Patients with liver diseases such as cirrhosis or secondary portal hypertension bleeding caused by esophageal and gastric varices or kidney diseases requiring dialysis or kidney transplantation or those with abnormal liver and kidney function (ALT AST BUN exceeding 1.5 times the upper limit of normal or blood Cr exceeding the upper limit of normal); 4.Patients who have been taking hormones and/or immunosuppressants for a long time; 5.Patients with impaired consciousness or various psychiatric disorders who are unable to communicate normally; 6.Pregnant or lactating women or those with a recent pregnancy plan; 7.Patients who have participated in other clinical trials within the past month; 8.Patients with known allergies to any trial drugs or their components.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| case fatality rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Mechanical Ventilation Rate;CRP;ATAQ-IPF;Immunoglobulin;PCT;Pulmonary Function;Ferritin;Chest HRCT;SGRQ;mMRC;blood gas analysis;length of stay;T Cell Subsets;KL-6; | — |
Countries
China
Contacts
Public ContactFENG JIHONG
The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Outcome results
None listed